Indivumed and CELLphenomics Announce Partnership

Von der Europäischen Union finanziertes Projekt soll zu neuen Therapieansätzen verschiedener solider Tumorarten führen

Indivumed GmbH (“Indivumed”) and CELLphenomics GmbH (“CELLphenomics”) today announced a partnership to create a unique platform for faster and more efficient discovery and validation of therapeutic targets.

Dr. Christian Regenbrecht, CEO of CELLphenomics (2nd from left) and Prof. Dr. Hartmut Juhl, CEO and founder of Indivumed (2nd from right) are pleased about the agreed partnership. ( Picture: © Indivumed)

The new platform combines Indivumed’s AI-driven oncology analytics with CELLphenomics’ expertise in creating organoid models to identify therapeutically relevant targets and validate these targets in-vitro. The partnership will accelerate cancer drug development by linking in-silico target discovery and development with matched patient-derived tumor models for downstream validation.

“Leveraging our multi-omics database and AI-driven oncology analytics is what allows us to decipher the complex mechanisms of cancer in order to drive the development of precision oncology,” said Prof. Dr. Hartmut Juhl, CEO and Founder of Indivumed. “By partnering with CELLphenomics, we will be able to quickly validate therapeutically relevant targets to identify new treatment approaches and accelerate cancer drug development in the future.”

The partnership announcement comes after Indivumed was awarded €4.3 million by the European Union Structural Fund ERDF to accelerate drug development and personalize treatments for cancer. CELLphenomics was selected by Indivumed as a partner due to the company’s technological capabilities and scientific expertise. Initially, the partnership will focus on cancer types with the greatest current medical need.

“Indivumed’s comprehensive database and advanced AI capabilities are critical for identifying therapeutically relevant targets,” said Dr. Christian Regenbrecht, CEO of CELLphenomics. “Combining these targets with CELLphenomics patient-derived models and in-vitro assays will enable reliable conclusions to be drawn about the treatability of the tumor and its functional causes of therapeutic success and failure.”

Based on the highly standardized cancer biospecimen collections through Indivumed’s Clinical Network, capturing the molecular reality of each patient’s disease is key to the project. Having generated the most comprehensive and deepest multi-omic dataset for cancer biology worldwide, Indivumed will leverage advanced analytical techniques to extract biological insights from this complex data. Indivumed’s analytical platform, nRavel®, will identify, characterize, and prioritize potential targets for the selected tumor types. The patient-based cellular models provided by CELLphenomics will now be derived from the same tumors. This means that the whole process – from tissue and data collection to identification and validation – will utilize the same data and tissue.

More News

Onco AI-Med meeting at Indivumed: Dr. David Kerr, Nils Schumacher, Prof. Gerry Melino, Nina Gabelia, Dr. John Marshall, Dr. Takayuki Yoshino, Prof. Hartmut Juhl, Dr. Sun Young Rha, Dr. Jesus Garcia-Foncillas, Dr. Carlos Sampaio and Dr. David Gallagher (fr
Onco AI-Med meeting at Indivumed: Dr. David Kerr, Nils Schumacher, Prof. Gerry Melino, Nina Gabelia, Dr. John Marshall, Dr. Takayuki Yoshino, Prof. Hartmut Juhl, Dr. Sun Young Rha, Dr. Jesus Garcia-Foncillas, Dr. Carlos Sampaio and Dr. David Gallagher (from left to right) (Picture: Indivumed)

Indivumed Hosts Onco AI-Med Annual Board Meeting in Hamburg

Indivumed Therapeutics (“Indivumed”) welcomed members of the Oncology Alliance For Individualized Medicine (“Onco AI-Med”) to its global headquarters in Hamburg, ...

Read more …
For academic research, MHH will receive access to the data generated within the partnership by working with Evotec’s AI-driven analytics software PanHunter. (Picture: © Evotec)

Evotec enters partnership with Hannover Medical School

Evotec SE announced that the Company has entered a partnership with Hannover Medical School (“MHH”), one of the leading German universities, to ...

Read more …

Indivumed Celebrates 20th Anniversary

Indivumed GmbH (“Indivumed”) today celebrated the company’s 20th anniversary milestone. Founded in Hamburg, Germany on April 5, 2002, Indivumed has rapidly expanded to ...

Read more …